Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 569-581

  Shahnazari, Mohammad ^a   Yao, Wei ^a   Wang, Bob ^a   Panganiban, Brian ^b,c   Ritchie, Robert O ^b,c   Hagar, Yolanda ^d   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c Lawrence Berkeley National Laboratory   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alendronate; Bone strength; PTH; raloxifene; treatment withdrawal

Indexed keywords

ALENDRONIC ACID; CREATININE; DEOXYPYRIDINOLINE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE BOWING; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; CANCELLOUS BONE; COMPRESSIVE STRENGTH; CONTROLLED STUDY; CORTICAL BONE; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; SCANNING ELECTRON MICROSCOPY; TRABECULAR BONE; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERTEBRA;

AMINO ACIDS; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMUR; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SPINE; TIBIA; WEIGHT-BEARING; X-RAY MICROTOMOGRAPHY;

EID: 79951848519     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.249     Document Type: Article

References (41)

1. Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002; 23: 508-516. (Pubitemid 34925644)
2. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002; 23: 524-528. (Pubitemid 34925646)
3. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-1441. (Pubitemid 32402100)
4. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296: 2927-2938. (Pubitemid 46021497)
5. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone(1-84) for osteoporosis. N Engl J Med. 2005; 353: 555-565. (Pubitemid 41138937)
6. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16: 925-931. (Pubitemid 32332303)
7. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164: 2024-2030. (Pubitemid 39390560)
8. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD,. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000; 15: 944-951. (Pubitemid 30233419)
9. Fuchs RK, Phipps RJ, Burr DB,. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res. 2008; 23: 1689-1697.
10. Iwaniec UT, Samnegard E, Cullen DM, Kimmel DB,. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone. 2001; 29: 352-360. (Pubitemid 32930062)
11. Verhulp E, van Rietbergen B, Muller R, Huiskes R,. Indirect determination of trabecular bone effective tissue failure properties using micro-finite element simulations. J Biomech. 2008; 41: 1479-1485.
12. Shahnazari M, Yao W, Dai W, et al. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone. 2010; 46: 1267-1274.
13. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
14. Akhter MP, Cullen DM, Gong G, Recker RR,. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone. 2001; 29: 121-125. (Pubitemid 32734492)
15. Ladd AJ, Kinney JH, Haupt DL, Goldstein SA,. Finite-element modeling of trabecular bone: comparison with mechanical testing and determination of tissue modulus. J Orthop Res. 1998; 16: 622-628. (Pubitemid 28512444)
16. van Rietbergen B, Weinans H, Huiskes R, Odgaard A,. A new method to determine trabecular bone elastic properties and loading using micromechanical finite-element models. J Biomech. 1995; 28: 69-81. (Pubitemid 24343733)
17. Ulrich D, Rietbergen B, Laib A, Ruegsegger P,. Mechanical analysis of bone and its microarchitecture based on in vivo voxel images. Technol Health Care. 1998; 6: 421-427. (Pubitemid 29090464)
18. Eswaran SK, Gupta A, Adams MF, Keaveny TM,. Cortical and trabecular load sharing in the human vertebral body. J Bone Miner Res. 2006; 21: 307-314. (Pubitemid 43265297)
19. Gunness-Hey M, Hock JM,. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone. 1989; 10: 447-452. (Pubitemid 20114926)
20. Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE,. Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats. J Bone Miner Res. 1996; 11: 169-177. (Pubitemid 26054174)
21. Chao EY, Inoue N, Koo TK, Kim YH,. Biomechanical considerations of fracture treatment and bone quality maintenance in elderly patients and patients with osteoporosis. Clin Orthop Relat Res. 2004; 425: 12-25. (Pubitemid 39062745)
22. Ulrich D, van Rietbergen B, Laib A, Ruegsegger P,. The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone. 1999; 25: 55-60. (Pubitemid 29322061)
23. Goulet RW, Goldstein SA, Ciarelli MJ, Kuhn JL, Brown MB, Feldkamp LA,. The relationship between the structural and orthogonal compressive properties of trabecular bone. J Biomech. 1994; 27: 375-389. (Pubitemid 24102051)
24. Zhang L, Takahashi HE, Inoue J, et al. Effects of intermittent administration of low dose human PTH(1-34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles. Bone. 1997; 21: 501-506. (Pubitemid 28029692)
25. Keaveny TM, Hoffmann PF, Singh M, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008; 23: 1974-1982.
26. Rockoff SD, Sweet E, Bleustein J,. The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae. Calcif Tissue Res. 1969; 3: 163-175.
27. Turner CH, Burr DB,. Basic biomechanical measurements of bone: a tutorial. Bone. 1993; 14: 595-608. (Pubitemid 23198821)
28. Nyman JS, Roy A, Reyes MJ, Wang X,. Mechanical behavior of human cortical bone in cycles of advancing tensile strain for two age groups. J Biomed Mater Res A. 2009; 89: 521-529.
29. Currey JD, Brear K, Zioupos P,. The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech. 1996; 29: 257-260. (Pubitemid 26010608)
30. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003; 88: 1150-1156. (Pubitemid 36337769)
31. Fox J, Newman MK, Turner CH, Guldberg RE, Varela A, Smith SY,. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys. Calcif Tissue Int. 2008; 82: 212-220.
32. Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE,. Prolonged Treatments with Anti-Resorptive Agents and PTH Have Different Effects on Bone Strength and the Degree of Mineralization in Old Estrogen Deficient Osteoporotic Rats. J Bone Miner Res. 2009; 1-43.
33. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R,. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int. 2008; 19: 529-535.
34. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349: 1207-1215. (Pubitemid 37152030)
35. Cosman F, Lindsay R,. Therapeutic potential of parathyroid hormone. Curr Osteoporos Rep. 2004; 2: 5-11.
36. Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone. 2009; 44: 113-119.
37. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY,. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007; 41: 321-330. (Pubitemid 47199143)
38. Fox J, Miller MA, Recker RR, Turner CH, Smith SY,. Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1-84 for 16 months on trabecular and cortical bone structure and biomechanical properties of the proximal femur. Calcif Tissue Int. 2007; 81: 53-63. (Pubitemid 47030207)
39. Compston JE,. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2007; 40: 1447-1452. (Pubitemid 46756408)
40. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM,. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16: 157-165. (Pubitemid 32046201)
41. Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE,. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. J Bone Miner Res. 2009; 24: 209-220.